PF-05089771
PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated [sodium channel] blocker under development by Pfizer as a novel analgesic. As of June 2014, it has completed Phases of [clinical research|phase II] clinical trials for wisdom tooth removal and primary erythromelalgia.